why don't I ever see one. Are they advertising on the biggest loser? I never watch that. I am not in the target market, so they are targeting well.
I believe the correct term for George and Weezie's firm is: paid bear. No company could be that stupid, they must be bought and paid for. People are wise to Tillison's and other bio-short manipulative methods by now and ignore them.
It's still 10%, if this is the last cut. Management did a great job of hedging and made a big mistake buying a company before the decline (in hindsight). The good part of the acquisition is apparently the deal was done for bloated stock, but the bad part was acquiring debt. It's a hold at this price IMO i'm not selling and probably not buying any more until the price stabilizes.
agreed with your last statement PFE takes them out. I know the new Sr. Dir and she's working hard to try and turn the Bel situation around while the chief commercial officer is going around giving talks to students about how to screw up a launch. Nice, I wonder how much they pay him for this.
I am surprised anyone loaned IMGN $200MM for Kadcyla revs. It's going to take a lot longer than 2-3 years if ever for them to get their money back IMO.
was that George Jefferson or Weezie that issued the downgrade. EXAS is movin on up! Only posters over 50 will get that.
On Linked-in John writes: "Looking for another Exuberaesque brand planning story. I'll be giving a lecture to the students in the pharmaceutical management program...on the brand planning process and could use a few more what-not-to-do anecdotes".
Here's and idea for you John, are you familiar with BELVIQ? How is that working for you, ARNA, Eisai ARNA shareholders? On the + side, at least Eisai hired a new Sr. Director of Marketing that is very experienced. Hoping for a turn around, but had to laugh at this question as is he was having a difficult time trying to find a bad branding story. At least the name is pretty good. If they would get a better TV commercial and invest in some advertising...then develop LAR, smoking, addictions, Bel-Phen, other countries we might just have something that sells!!!
IMGN traded upside for 2-3 years of financial runway to find another drug that's wholly owned to work, or some combo of investing in the BT drug. So far, nothing has worked past phase I when IMGN was in charge of the trials. Good luck.
nobody knows where or when the bottom is or when, if ever, prices will reverse and start going up. If management does a great job and the commodity price recovers the stock could return to $10, 15 or 20. If not, this stock could go to zero due to debt. This is a real crp-shoot. I wish I had not bought the stock (higher), but now i'm an investor. I was banking on the crazies in the Middle East to do something to get the price back up, either the cartel by intention, or the radicals through their bad intentions. It's not very predictable, so for now, over-supply and technicals are driving prices lower.
How will this study lead to more sales, additional indications, etc. I am not seeing the benefit to shareholder value.
yes, waiting is a great strategy, they seem to have mastered waiting and puffing up the stock briefly to sell secondaries and to cash in on their cheap options. Have I missed any of their other major executive skills?
nearly the end of the month and they have nothing for us to report, more broken promises, delays, etc. They got their money and sold their options for now, they need the price to go down to reload at a low price. They will spin a new tale when it's time to sell their options.
Eisai did hire a talented Marketing Sr. Director from Sanofi, so at least they did something. If she doesn't have the budget, it's difficult to win. Jack picked the wrong partner for Belviq, so we need another winner from the pipeline.
Let's do the math 29MM shares short x $1.73= 50MM. If they paid $1MM for the recommendation change, not a bad ROI. All speculation/opinion. Goldman is obviously short, or trying to accumulate, or actiing on behalf of a client in EXAS and Oil. It's good to be the king.
this is an 8 kid study, not material. More important, I noticed that Eisai hired an experienced and talented senior level marketing pro from Sanofi for Belviq. Hopefully, she can get this turned around, if she has the budget.
is this a surprise? Of course it's going to take some time and more insurance coverage for a significant rise in volume. I have been saying that for months, which is why I have been selling calls against my stock. Eventually I think EXAS will be acquired for $30-40+. I can be patient and trade around the core position. You don't have to be a Goldman analyst to know launching a new product for a new market takes time.
the stock went from $3-4 to almost $10, so this was a timely raise. This is what biotech companies do unless they are acquired.